China Biotech Services Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, Group expected to record a net loss attributable to the owners of the Company of approximately HKD 90,000,000. In contrast to the Loss, the Group recorded a net profit attributable to the owners of the Company of approximately HKD 258,087,000 for the corresponding period in 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.335 HKD | -15.19% | +4.69% | -56.49% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.49% | 48.73M | |
+26.12% | 89.41B | |
-21.82% | 77.49B | |
+2.39% | 27.13B | |
-8.49% | 17.53B | |
+1.07% | 17.14B | |
+1.70% | 15.58B | |
-25.79% | 12.92B | |
+71.47% | 13.19B | |
+80.01% | 13.29B |
- Stock Market
- Equities
- 8037 Stock
- News China Biotech Services Holdings Limited
- China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023